CVS HEALTH Corp
boothcheck covers CVS HEALTH Corp (CVS) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Retail prescription volume keeps rising while the drug-benefit arm loses ground: prescriptions filled reached 1,808.8 million on a 30-day equivalent basis in 2025, up 5.4%, while pharmacy claims processed fell 0.9% on the same basis. • Reported operating income dropped to $4,660 million in 2025 from $8,516 million a year earlier, a fall the filing attributes ⟦"primarily due to a $5.7 billion goodwill impairment charge"⟧ against the health insurance business, which is why every backward-lookin
Is CVS overvalued? See what's priced in →
1,812 institutional managers reported holding CVS in 13F filings for the quarter ended 2026-03-31. Together they hold about 84% of the company; the top 10 hold 44%. 122 opened new positions that quarter. Held by BlackRock, Vanguard Group, Capital Group (American Funds), among others. On the short side, 23.2M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CVS has cut its share count 3.5% over the past five years, spending $8.54B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $2.66 a share annually. Cash returned over the past three years: $9.18B in dividends and $3.02B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CVS over the trailing three years: 2023: 1 buy totaling $141k; 2024: 5 buys totaling $559k; 2025: 3 buys totaling $2.10M. 26 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CVS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +0.5% | -6.2% |
| 2023-11-02 | +0.9% | +15.6% |
| 2024-02-08 | +1.8% | -7.1% |
| 2024-05-02 | -18.6% | +2.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CVS's latest 8-K filings: 2026-08-17 (items 5.02, 7.01, 9.01); 2026-08-05 (items 2.02, 9.01); 2026-05-18 (items 5.02, 5.07); 2026-05-06 (items 2.02, 9.01); 2026-03-19 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.